Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features

Cancer

Volumn 97, Issue 5, 2003, Pages 1276-1284

  Van den Bent, Martin J ^a   Looijenga, Leendert H J ^a   Langenberg, K ^a   Dinjens, Winand ^a   Graveland, Wilfried ^a   Uytdewilligen, Ludo ^a   Sillevis Smitt, Peter A ^a   Jenkins, Robert B ^b   Kros, Johan M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAYO CLINIC   (United States)

Author keywords

19q; 1p; Chemotherapy; Low grade glioma; Oligoastrocytoma; Oligodendroglioma; Prognosis

Indexed keywords

LOMUSTINE; MONOCLONAL ANTIBODY KI 67; PROCARBAZINE; PROTEIN P53; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL FEATURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SEIZURE; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOMUSTINE; MUTATION; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0344863443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11187     Document Type: Article

References (25)

1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 1994;12:2013-2021.
2. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology. 1998;51:1140-1145.
3. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79:1381-1391.
4. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
5. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144-4152.
6. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-1190.
7. Bigner SH, Matthews MR, Rasheed BKA, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999;155:375-386.
8. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
9. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845.
10. Bauman GS, Ino Y, Yeki K, Fisher BJ, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys. 2000;48:825-830.
11. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
12. Kersemaekers AM, Mayer F, van Weeren P, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol. 2002;20:1551-1561.
13. Stock C, Ambros IM, Mann G, Gadner H, Amann G, Ambros PF. Detection of 1p36 deletions in paraffin section of neuroblastoma tissues. Genes Chromosomes Cancer. 1993;6:1-9.
14. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56:1098-1104.
15. Hoang-Xuan K, Huguet S, Mokhtari K, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2002;57:1278-1281.
16. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992;31:431-46.
17. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74:1784-1791.
18. Coons S, Johnson PC, Pearl DK. The prognostic significance of K1-67 labeling indices for oligodendrogliomas. Neurosurgery. 1997;41:878-885.
19. Kros JM, Hop WCJ, Godschalk JJCJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer. 1996;78:1107-1113.
20. van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 2001;57:340-342.
21. Zlatescu MC, Tehrani Yazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;18:6713-6715.
22. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol. 2002;61:58-63.
23. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. 2002;103:267-275.
24. Jeuken JWM, Sprenger SHE, Wesseling P, et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. 1999;58:606-612.
25. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000;92:983-990